Reaction

Enterocolitis Infectious reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 918 reports · 47 co-occurring drugs

As of the last recalculation, Enterocolitis Infectious appears in 918 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is PEGASPARGASE (PRR 39.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pegaspargase	21	39.8	39.8
Durvalumab	29	33.3	33.4
Mometasone	26	33.0	33.1
Vincristine Sulfate	38	30.6	30.7
Mercaptopurine	19	25.3	25.4
Pertuzumab	29	24.9	25.0
Gemcitabine Hydrochloride	51	23.0	23.0
Granisetron Hydrochloride	10	21.9	22.0
Paclitaxel	82	20.5	20.5
Cytarabine	51	20.3	20.3
Irinotecan Hydrochloride	11	19.6	19.6
Obinutuzumab	14	19.6	19.6
Prochlorperazine	22	18.4	18.4
Mesna Injection	6	16.6	16.6
Bendamustine Hcl	11	16.3	16.3
Mesna	6	16.3	16.3
Leucovorin Calcium	13	15.6	15.6
Sorafenib	14	15.5	15.5
Gemcitabine	26	15.4	15.4
Blinatumomab	7	15.3	15.3
Granisetron	7	15.2	15.2
Docetaxel Anhydrous	40	14.0	14.0
Docetaxel	40	14.0	14.0
Ado-Trastuzumab Emtansine	5	13.5	13.5
Atezolizumab	22	13.1	13.1
Trastuzumab	37	12.7	12.7
Carboplatin	64	12.2	12.2
Thiotepa	5	11.9	11.9
Cetuximab	16	11.8	11.8
Cyclophosphamide Injection, Solution	84	11.7	11.7
Cyclophosphamide	84	11.7	11.7
Cyclophosphamide For Injection	84	11.7	11.7
Fosaprepitant Dimeglumine	7	11.6	11.6
Paclitaxel (Aibumin-Bound)	40	11.5	11.5
Brentuximab Vedotin	5	11.1	11.1
Doxorubicin	41	10.9	10.9
Vismodegib	4	10.2	10.2
Azacitidine	13	10.1	10.1
Ipilimumab	18	9.6	9.6
Cisplatin	31	9.3	9.3
Azacitidine For	7	8.8	8.8
Ofatumumab	12	8.3	8.3
Iohexol	3	8.2	8.2
Gefitinib	3	7.6	7.6
Dasatinib	12	7.4	7.4
Carfilzomib	8	6.5	6.5
Pegfilgrastim	16	3.7	3.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.